Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Three beta3-adrenoceptor agonists in preclinical stage at BMS

April 26, 1996

MTP inhibitor BMS-201038 in development for hyperlipidemia

April 26, 1996

Colestimide NDA filing imminent

April 26, 1996

Otsuka evaluates hypolipidemic agents

April 26, 1996

Sanofi Winthrop discovers potent ATP-citrate lyase inhibitor

April 26, 1996

NTE-122: Nissin Foods' ACAT inhibitor

April 26, 1996

FemPatch approval imminent in USA

April 19, 1996

FDA designates orphan drug for Peyronie's disease

April 19, 1996

Troglitazone NDA filing expected soon

April 19, 1996

RF-1051 cleared to enter phase II

April 19, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...